Freedom Capital analyst Gene Mannheimer initiated coverage of Hinge Health (HNGE) with a Buy rating and $59 price target Hinge is “the market leader” in digital-first musculoskeletal therapy and “just scratching the surface” in a $60B-plus MSK industry, the analyst tells investors. Given the firm’s forecast for 23% growth this year and “industry-leading, software-like margins” of 82-83%, it would use current weakness in the shares to own the name, the analyst added.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HNGE:
- Hinge Health: Strong Usage Momentum, Conservative Growth Expectations, and Competitive Moat Support Buy Rating
- Hinge Health price target lowered to $60 from $71 at Piper Sandler
- Hinge Health initiated with an Overweight at Wells Fargo
- Hinge Health price target lowered to $70 from $72 at KeyBanc
- Hinge Health: Solidifying MSK Leadership with Undemanding Valuation and Significant Upside into 2026